Ország: Dél-afrikai Köztársaság
Nyelv: angol
Forrás: South African Health Products Regulatory Authority (SAHPRA)
Schering
ADVANTAN SCALP SOLUTION SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): ADVANTAN SCALP SOLUTION Corticoid skin preparations COMPOSITION 1 mL Advantan contains methylprednisolone aceponate (21-acetoxy-11(beta-hydroxy-6alpha-methyl-17-propionyloxy- 1,4-pregnadiene-3,20-dione) 1 mg. PHARMACOLOGICAL CLASSIFICATION A. 13.4.1 Corticosteroids without anti-infective agents. PHARMACOLOGICAL ACTION Pharmacodynamic properties After topical application, Advantan Scalp Solution suppresses inflammatory and allergic skin reactions as well as reactions associated with hyperproliferation, leading to regression of the objective symptoms (erythema, oedema, weeping) and the subjective complaints (itching, burning, pain). The mechanism of action of methylprednisolone aceponate is not completely understood. It is known that methylprednisolone aceponate itself binds to the intracellular glucocorticoid receptor and this is especially true for the principal metabolite methylprednisolone-17-propionate, which is formed after cleavage in the skin. The steroid receptor complex binds to certain regions of DNA, thereby triggering a series of biological effects. The understanding of the mechanism of the anti-inflammatory action is more precise. Binding of the steroid receptor complex results in induction of macrocortin synthesis. Macrocortin inhibits the release of arachidonic acid and thus the formation of inflammatory mediators such as prostaglandins and leukotrienes. The immunosuppresive action of glucocorticoids can be explained by inhibition of cytokine synthesis and an antimitotic effect, which so far is not well understood. Inhibition of the synthesis of vasodilating prostaglandins or potentiation of the vasoconstrictive effect of adrenalin finally results in the vasoconstrictive activity of glucocorticosteroids. Pharmacokinetic pr Olvassa el a teljes dokumentumot